Continuous glucose monitors for people without diabetes: what the evidence actually supports
The stick-on sensors that show your blood sugar all day are now sold without a prescription, marketed to healthy people who want to 'optimize' their metabolism. The devices themselves work as advertised — what's genuinely unproven is whether reacting to every blip actually helps someone whose blood sugar was already normal to begin with.
Over-the-counter continuous glucose monitors (Abbott Lingo, Dexcom Stelo) reached the market through FDA clearance as general wellness devices, not through evidence that wearing one changes health outcomes in people without diabetes — those are different regulatory bars. The technology itself is accurate and real; what's unresolved is whether reacting to normal, expected glucose fluctuations in a metabolically healthy person changes anything that matters. The evidence is much stronger for one specific group: people whose own lab work (HbA1c, fasting insulin) already shows early insulin resistance, where real-time feedback has a genuine behavior-change rationale behind it.
- Dexcom Stelo and Abbott Lingo were cleared by the FDA in 2024 through the 'general wellness' or non-diabetes pathway, not by demonstrating that CGM use in healthy adults improves a health outcome.
- Recent systematic reviews of CGM as a behavior-change tool in people without diabetes describe the evidence for improving glycemic, weight or behavioral outcomes as still unclear.
- A meal 'spike' that a CGM flags in someone with normal fasting glucose and HbA1c is frequently a normal physiological response, not a warning sign — the marketing narrative around 'glucose spikes' borrows urgency from diabetes care that doesn't automatically transfer.
- The more defensible use case is narrower and better supported: someone with lab results already in the prediabetes range gets a real, motivating feedback loop while making the diet and exercise changes that evidence already supports for that specific situation.
- Lingo is explicitly not FDA-cleared for diagnosing or managing diabetes; Stelo is cleared for adults with or without diabetes who don't use insulin — neither is a diagnostic replacement for a blood test.
What each device is actually cleared to do
Regulatory clearance, precisely
| Device | FDA clearance | Not cleared for |
|---|---|---|
| Dexcom Stelo | Adults with or without diabetes who don't use insulin, to understand how diet and exercise affect glucose | Insulin dosing decisions; use by people on insulin |
| Abbott Lingo | Adults 18+ as a general health and wellness tool, explicitly for people without diabetes | Diagnosing, monitoring or managing diabetes of any kind |
The sensor technology itself is not in question — it descends directly from Dexcom's and Abbott's prescription CGMs, which are genuinely well-validated for glucose accuracy in people with diabetes. What changed is who is allowed to buy one and why, not the strength of evidence for the new use case.
The actual evidence for use in metabolically healthy adults
- Systematic reviews examining CGM as a behavior-change tool in people without diabetes describe the effect on glycemic control, weight and other outcomes as still unclear — the trials that exist are small, short and inconsistent.
- A rise in glucose after a meal — the 'spike' the apps flag — is a normal physiological response in someone with normal fasting glucose and HbA1c. There is no established threshold at which a post-meal reading in a metabolically healthy person predicts future disease the way an actually abnormal HbA1c does.
- Day-to-day glucose readings are also genuinely variable with sleep, stress, hydration and sensor placement, which means a single alarming-looking spike is frequently noise rather than a signal worth acting on.
- None of this means the sensor is wrong. It means the interpretive layer — the app telling a healthy person their glucose response to a banana is a problem — is running ahead of what the outcome research actually supports.
Who this genuinely makes sense for
Ranked on: FDA clearance status and how well the marketed use case matches what has actually been evaluated, not brand reputation.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Abbott Lingo (2-sensor pack) | FDA-cleared for wellness use; genuinely useful only with a specific reason to watch the number | GRADE BPromising |
| 2 | Dexcom Stelo | Same evidence gap, cleared for a slightly broader group | GRADE BPromising |
| 3 | Using a CGM to self-diagnose 'insulin resistance' without lab work | Not a substitute for the actual test | GRADE DInsufficient or unsafe |
- 01
Abbott Lingo (2-sensor pack)
GRADE BPromisingFDA-cleared for wellness use; genuinely useful only with a specific reason to watch the numberExplicitly cleared for adults without diabetes as a general wellness tool, not for diagnosing or managing any glucose condition. Best matched to someone who already has lab-confirmed early insulin resistance and wants real-time feedback while making changes — treated as a general 'optimization' purchase for an already-healthy person, the outcome evidence does not yet support the premise the marketing leans on.
- 02
Dexcom Stelo
GRADE BPromisingSame evidence gap, cleared for a slightly broader groupCleared for adults with or without diabetes who don't use insulin, aimed at understanding diet and exercise effects on glucose. The same caveat applies as with Lingo: cleared as an accurate sensor for a non-diagnostic purpose, not validated as improving outcomes in people who are not already showing early metabolic dysfunction on standard labs.
- 03
Using a CGM to self-diagnose 'insulin resistance' without lab work
GRADE DInsufficient or unsafeNot a substitute for the actual testA CGM measures interstitial glucose, not insulin, and cannot diagnose insulin resistance on its own — fasting insulin and HbA1c, standard cheap blood tests, are what actually establish that. Treating a pattern of CGM readings as a diagnosis skips the test that would actually confirm or rule out the thing the readings are being used to worry about.
Frequently asked questions
Is a continuous glucose monitor worth it if I don't have diabetes?
It depends on why you'd use it. If your own blood work already shows early insulin resistance (elevated HbA1c or fasting insulin), a CGM can provide genuinely motivating real-time feedback while you make evidence-supported changes. As a general 'optimization' tool for someone with normal labs, the outcome evidence is still unclear — you'd be reacting to normal physiological variation without a proven benefit.
Are Lingo and Stelo approved to diagnose diabetes or prediabetes?
No. Lingo is explicitly cleared as a wellness tool for people without diabetes and is not cleared to diagnose, monitor or manage diabetes. Stelo is cleared for people with or without diabetes who don't use insulin, to understand how food and activity affect glucose — neither replaces the blood tests (HbA1c, fasting glucose, fasting insulin) that actually diagnose prediabetes or diabetes.
Is it bad to have glucose 'spikes' after meals if I don't have diabetes?
A rise in glucose after eating is a normal, expected response in someone with normal fasting glucose and HbA1c. There is no established threshold showing that a post-meal reading in a metabolically healthy person predicts future disease the way an actually abnormal lab value does — the alarm framing in a lot of CGM marketing outruns what's actually been shown.
Can a CGM cause harm if I don't have a metabolic condition?
The most reported downside is behavioral: reacting anxiously to normal glucose fluctuations, or adopting unnecessarily restrictive eating, in someone who was never at meaningful risk. If wearing one makes you more anxious about food rather than more informed, that outweighs the device's benefit for most healthy users.
Keep reading
- Which blood tests are best for tracking longevity?
HbA1c and fasting insulin — the tests that actually diagnose the early insulin resistance a CGM is genuinely useful for tracking.
- Which home blood pressure monitor is actually accurate?
The same 'check what's actually validated, not what's marketed' approach applied to a different home device.
More in Biomarkers & testing
- Grip strength testing for longevity: a five-second measurement with more mortality evidence than most blood tests
Grip strength predicts mortality, disability and cardiovascular death across large cohorts, independent of age. Here is how to measure it properly, what a low reading means, and which tool actually matches the research.
- Which home blood pressure monitor is actually accurate? Most on the market have never been validated
Hypertension is the single largest modifiable driver of death worldwide, and home monitoring changes treatment — but most cuffs sold have never passed independent accuracy testing. Here is how to check, and one that has.
- What lab tests monitor efforts to extend lifespan?
Lab tests ranked by whether they meaningfully monitor lifespan-relevant progress: blood pressure and lipid panels, HbA1c and fasting glucose, kidney and liver function, inflammatory markers, and popular 'biological age' tests that do not change any actionable decision.
- Which blood tests are best for tracking longevity?
ApoB, Lp(a), HbA1c, hs-CRP and a handful of others predict lifespan in large studies and cost little. Here is the core panel, what each marker means, and what to skip.
- Best longevity blood tests and biomarkers to monitor.
The monitoring guide: each longevity biomarker with its evidence-based target range, how often to retest, what moves it, and when a change means something rather than noise.
- VO2 max testing for longevity: what it measures, and what the evidence actually shows
VO2 max is one of the strongest predictors of all-cause mortality in the research. What the test actually measures, how accurate estimates are, and where to get one.